These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 10628528)

  • 1. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model.
    Keshavan MS
    J Psychiatr Res; 1999; 33(6):513-21. PubMed ID: 10628528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain maturational processes and delayed onset in schizophrenia.
    Keshavan MS; Hogarty GE
    Dev Psychopathol; 1999; 11(3):525-43. PubMed ID: 10532623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is schizophrenia a neurodegenerative disorder?
    Rund BR
    Nord J Psychiatry; 2009; 63(3):196-201. PubMed ID: 19235629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Involvement of central neurotransmission systems in schizophrenia].
    Martres MP
    Therapie; 2008; 63(3):177-85. PubMed ID: 18718209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of neural synchrony and large-scale cortical networks during adolescence: relevance for the pathophysiology of schizophrenia and neurodevelopmental hypothesis.
    Uhlhaas PJ; Singer W
    Schizophr Bull; 2011 May; 37(3):514-23. PubMed ID: 21505118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity.
    Lieberman JA; Sheitman BB; Kinon BJ
    Neuropsychopharmacology; 1997 Oct; 17(4):205-29. PubMed ID: 9326746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia.
    Bossong MG; Niesink RJ
    Prog Neurobiol; 2010 Nov; 92(3):370-85. PubMed ID: 20624444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developmental trajectory of cognitive impairment in bipolar disorder: comparison with schizophrenia.
    Bora E
    Eur Neuropsychopharmacol; 2015 Feb; 25(2):158-68. PubMed ID: 25261263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions.
    Cannon TD; van Erp TG; Bearden CE; Loewy R; Thompson P; Toga AW; Huttunen MO; Keshavan MS; Seidman LJ; Tsuang MT
    Schizophr Bull; 2003; 29(4):653-69. PubMed ID: 14989405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schizophrenia in childhood and adolescence.
    Mala E
    Neuro Endocrinol Lett; 2008 Dec; 29(6):831-6. PubMed ID: 19112396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmentally moderated expressions of the neuropathology underlying schizophrenia.
    Walker EF
    Schizophr Bull; 1994; 20(3):453-80. PubMed ID: 7526447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
    Meyer U; Feldon J
    Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dysplastic net hypothesis: an integration of developmental and dysconnectivity theories of schizophrenia.
    Bullmore ET; Frangou S; Murray RM
    Schizophr Res; 1997 Dec; 28(2-3):143-56. PubMed ID: 9468349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive dysfunction in schizophrenia: a perspective from the clinic to genetic brain mechanisms.
    Tan HY
    Ann Acad Med Singap; 2009 May; 38(5):420-5. PubMed ID: 19521642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms.
    Thompson JL; Pogue-Geile MF; Grace AA
    Schizophr Bull; 2004; 30(4):875-900. PubMed ID: 15954196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurodevelopmental model of schizophrenia: update 2005.
    Rapoport JL; Addington AM; Frangou S; Psych MR
    Mol Psychiatry; 2005 May; 10(5):434-49. PubMed ID: 15700048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
    Jann MW
    Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synaptic dysfunction in schizophrenia.
    Yin DM; Chen YJ; Sathyamurthy A; Xiong WC; Mei L
    Adv Exp Med Biol; 2012; 970():493-516. PubMed ID: 22351070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.